“We have made significant progress with the ImCardia™, as well as with our minimally invasive devices, the ImCardia-MIS and the CORrolla,” said Amir Loshakove, CEO of CorAssist. “This additional capital enables us to continue the execution of our strategy of leadership in therapeutic devices for DHF.”
The ImCardia™ is an elastic device placed on the outer surface of the left ventricle. A breakthrough preclinical study has shown the ImCardia™ to harness elastic energy produced by the left ventricle during systole (contraction) and to release the energy and assist the heart during diastole (relaxation).
The Company has successfully implanted the ImCardia™ in six patients in a multi-center safety clinical trial. Patients have shown the ImCardia™ to be safe with three months, six months and with the first two patients, nearly 12 months follow-up.
“We are very excited to be investors in CorAsisst,” said Dr. Dan J Gelvan, the Managing Director of LifeSciences at Aurum Ventures MKI. “There are currently no effective solutions to treat patients with diastolic heart failure, which account for nearly half of the heart failure population. The ImCardia-MIS and the CORolla have the potential to be real breakthroughs in the cardiothoracic and cardiology market.”
The CORolla is an elastic device placed inside the left ventricle through minimal invasive procedure. Preclinical studies have shown the device to be safe and to improve diastolic function. First implantation in humans is expected early next year.
“I am convinced that with our new and current investors, and with our team, we can achieve our goals and introduce a line of therapeutic devices that will make a difference for DHF patients,” said Amir Loshakove, CEO of CorAssist.
About CorAssist Cardiovascular Ltd. CorAssist is a medical device company developing novel therapeutic devices for Diastolic Heart Failure (DHF). DHF is a condition in which the heart becomes stiff and/or fails to relax, and fills inadequately. Today, there are no evidence based therapeutic options for the estimated 2.5 million DHF patients in the United States.
The company’s “spring-like” devices harness elastic energy produced by the left ventricle during systole (contraction) and release the energy during diastole (relaxation). The released energy assists the left ventricle to overcome its stiffness by “springing back” an appropriate amount to improve relaxation and blood filling.
CorAssist was founded in 2002 by Dr. Yair Feld, Dr. Shay Dubi, and Dr. Yotam Reisner, at Naiot Incubator.
Contact:
CorAssist Cardiovascular Ltd. Mirit Lavie, Administration Manager Tel: +972 9 955 4500 Fax: +972 9 955 4600 mirit_l@corassist.com
